Summary of participant characteristics
| . | DCS vs MRI . | Voxelotor . |
|---|---|---|
| n | 8 | 8 |
| Age, y | 14 (11-17) | 9 (7-12) |
| Male, n (%) | 2 (25) | 5 (63) |
| Weight, kg | 60 (45-71) | 33 (23-43) |
| Hb, g/dL | 9.9 (8.3-11.1) | 9.1 (8.2-9.9) |
| % Reticulocyte count | — | 8.1 (5.2-11.0) |
| % White blood cell count | — | 7.5 (5.0-10.0) |
| LDH, U/L | — | 455 (268-571) |
| Bilirubin, μmol/L | — | 2.3 (1.4-3.2) |
| HbF, % | — | 22.4 (10.7-34.1) |
| HbSS genotype, n (%) | 8 (100) | 8 (100) |
| Current hydroxyurea use, n (%) | 7 (88) | 8 (100) |
| . | DCS vs MRI . | Voxelotor . |
|---|---|---|
| n | 8 | 8 |
| Age, y | 14 (11-17) | 9 (7-12) |
| Male, n (%) | 2 (25) | 5 (63) |
| Weight, kg | 60 (45-71) | 33 (23-43) |
| Hb, g/dL | 9.9 (8.3-11.1) | 9.1 (8.2-9.9) |
| % Reticulocyte count | — | 8.1 (5.2-11.0) |
| % White blood cell count | — | 7.5 (5.0-10.0) |
| LDH, U/L | — | 455 (268-571) |
| Bilirubin, μmol/L | — | 2.3 (1.4-3.2) |
| HbF, % | — | 22.4 (10.7-34.1) |
| HbSS genotype, n (%) | 8 (100) | 8 (100) |
| Current hydroxyurea use, n (%) | 7 (88) | 8 (100) |
Data are reported as median (IQR) or count (percentage) for the DCS validation against MRI cohort (n = 8, first column) and voxelotor cohort at the time of screening (n = 8, second column).
HbF, fetal hemoglobin.